JRMS J Res Med Sci Journal of Research in Medical Sciences Journal of Research in Medical Sciences 1735-1995 1735-7136 Medknow Publications Pvt Ltd India JRMS-18-795 24381625 Original Article The effect of levamisole on mortality rate among patients with severe burn injuries Fatemi Mohammad J Salehi Hamid Akbari Hossein Alinejad Faranak Saberi Mohsen Mousavi Seyed J Soltani Majid Taghavi Shahrzad Payandan Hossein Department of Plastic and Reconstructive Surgery, Burn Research Center and Hazrat Fatemeh Hospital, Iran University of Medical Sciences, Tehran, IranDepartment of Surgery, Burn Research Center and Motahari Hospital, Iran University of Medical Sciences, Tehran, IranDepartment of Plastic and Reconstructive Surgery, Burn Research Center and Hazrat Fatemeh Hospital, Iran University of Medical Sciences, Tehran, IranDepartment of Infectious Disease Specialist, Burn Research Center and Motahari Hospital, Iran University of Medical Sciences, Tehran, IranDepartment of Medicine, Quran and Hadith Research Center and Department of Community Medicine, Baqiyatallah University of Medical Sciences, Tehran, IranDepartment of Community Medicine, Burn Research Center, Iran University of Medical Sciences and Mazandaran University of Medical Sciences, Tehran, IranDepartment of General Physician, Burn Research Center, Iran University of Medical Sciences, Tehran, IranDepartment of General Physician, Burn Research Center, Iran University of Medical Sciences, Tehran, IranDepartment of Psychologist, Shahid Lavasani Hospital, Social Security Organization, Tehran, Iran Address for correspondence:Mohammad Fatemi, Department of Plastic and Reconstructive Surgery, Burn Research Center and Hazrat Fatemeh Hospital, Iran University of Medical Sciences, Tehran, Iran mj-fatemi@tums.ac.ir September 2013 18 9 795 800 2822013 1182013 Copyright: © Journal of Research in Medical Sciences 2013

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background:

Burn injuries are one of the main causes of mortality and morbidity throughout the world and burn patients have higher chances for infection due to their decreased immune resistance. Levamisole, as an immunomodulation agent, stimulates the immune response against infection. Materials and Methods:

This randomized clinical trial was conducted in Motahari Burn Center, Tehran, Iran. Patients who had second- or third-degree burn with involvement of more than 50% of total body surface area (TBSA) were studied. The levamisole group received levamisole tablet, 100 mg per day. Meantime, both the levamisole and control groups received the standard therapy of the Burn Center, based on a standard protocol. Then, the outcome of the patients was evaluated. Results:

237 patients entered the study. After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group and 85 in the treatment group. The mean age of all patients (between 13 to 64 years) was 33.29 ± 11.39 years (Mean ± SD), and it was 33.86 ± 11.45 years in the control group and 32.57 ± 11.32 years in the treatment group. The mean percentage of TBSA burn was 64.50 ± 14.34 and 68.58 ± 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA. The mortality rate was 68 (61.8%) patients in the control group and 50 (58.8%) patients in the treatment group (P = 0.8). Conclusion:

According to this study, there was no significant relationship between improvement of mortality and levamisole consumption.

Materials and Methods:

This randomized clinical trial was conducted in Motahari Burn Center, Tehran, Iran. Patients who had second- or third-degree burn with involvement of more than 50% of total body surface area (TBSA) were studied. The levamisole group received levamisole tablet, 100 mg per day. Meantime, both the levamisole and control groups received the standard therapy of the Burn Center, based on a standard protocol. Then, the outcome of the patients was evaluated. Results:

237 patients entered the study. After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group and 85 in the treatment group. The mean age of all patients (between 13 to 64 years) was 33.29 ± 11.39 years (Mean ± SD), and it was 33.86 ± 11.45 years in the control group and 32.57 ± 11.32 years in the treatment group. The mean percentage of TBSA burn was 64.50 ± 14.34 and 68.58 ± 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA. The mortality rate was 68 (61.8%) patients in the control group and 50 (58.8%) patients in the treatment group (P = 0.8). Conclusion:

According to this study, there was no significant relationship between improvement of mortality and levamisole consumption.

Results:

237 patients entered the study. After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group and 85 in the treatment group. The mean age of all patients (between 13 to 64 years) was 33.29 ± 11.39 years (Mean ± SD), and it was 33.86 ± 11.45 years in the control group and 32.57 ± 11.32 years in the treatment group. The mean percentage of TBSA burn was 64.50 ± 14.34 and 68.58 ± 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA. The mortality rate was 68 (61.8%) patients in the control group and 50 (58.8%) patients in the treatment group (P = 0.8). Conclusion:

According to this study, there was no significant relationship between improvement of mortality and levamisole consumption.

Conclusion:

According to this study, there was no significant relationship between improvement of mortality and levamisole consumption.

Burn immunomodulation agent infection levamisole
</sec><sec><title>Introduction

Treatment of patients with extensive burns remains a major challenge, even with advances in burn care over recent decades. 1 Burn injuries are one of the main causes of mortality and morbidity throughout the world, and infections and inhalation injuries are the major causes of death following these injuries. 2,3,4,5,6,7,8,9

Burns greater than 30% of the total body surface area (TBSA) particularly affect the immune system. Both the innate and adaptive, especially the cellular, immune systems are influenced by the thermal injury, 10,11,12,13 and effector mechanisms of nonspecific and specific host defenses are impaired (phagocytosis, chemotaxis, lymphocyte proliferation, antibody production). 14,15,16,17,18,19 Severe burn injury also alters the T cell by inducing an imbalance in T helper (Th) cell functions, caused by a phenotypic imbalance in the regulation of Th1 and Th2 immune response. 20,21,22,23

Therefore, some ways have been developed to improve the immune response and host resistance to septic challenge in thermally injured patients. It has been indicated that consumption of polymyxin B and interleukin-2 can improve resistance against infections in the burned animal models. 24,25

Levamisole is a derivative of levo isomer of tetramisole, a potent broad-spectrum anthelmintic. 26,27 In 1972, its immunomodulation effect was observed. It has been used in many clinical trials to treat many diseases including colon carcinomas, breast cancer, advanced malignant diseases, aphthous stomatitis, childhood nephrotic syndrome, chronic idiopathic urticarial, bacterial infections, and HIV infection with different results.- 28,29,30,31,32,33,34 Levamisole stimulates the polymorpho-nuclear lymphocytes (PNL), macrophages, and T lymphocytes, and increases the chemotaxis and proliferation of these cells. Levamisole has an immunostimulant effect by proliferating natural killer cells, which kill T lymphocytes, virus-infected cells, and tumor cells. 24,30,35,36,37,38,39 Some studies have also shown that its consumption is almost effective in increasing immunity in burned human and animal models. 40,41,42,43,44

Because of this modulatory effect of levamisole on immune system and the impairment of this system in burned patients, a study was designed to evaluate the effect of this drug on the mortality of severe second- and third-degree burns over 50% TBSA.

Materials and Methods

This randomized parallel-group clinical trial study was conducted in Burn Center, Motahari Hospital, Iran University of Medical Sciences (IUMS), Iran from 7 July 2010 to 7 September 2011. The study was confirmed by the ethical committee of IUMS and was submitted in Iran clinical trial website (www.irct.ir). Written informed consent was obtained from all the participants (and/or their parents).

The study population included the patients who referred within 24 h of injuries with second- and/or third-degree thermal burns with more than 50% of TBSA. Patients with chemical burn, electrical burn, inhalation injury, underlying disease, and also the patients who expired within 72 h after hospitalization were excluded from the study. All of the admitted burn patients with 50% and more of TBSA who accepted to participate in the study were enrolled; thus, 237 patients entered the study. At the time of admission, they were randomly assigned to two groups of treatment and control. The levamisole group received levamisole tablet (Poorsina, Tehran, Iran) 100 mg/day until discharge from the hospital or death. Except this part of treatment, patients were treated separately based on their condition by surgeon′s decisions.

Age, sex, etiology, percentage of the burned area, and outcome of each patient were registered.

The data were analyzed using the independent sample t-test, chi-square test, and analysis of variance (ANOVA) by means of SPSS software, with P < 0.05 considered as the level of significance.

Results

From 7 July 2010 until 7 September 2011, 237 patients aged 13 years and over were enrolled in the study. Data were collected from 133 patients (78.9% males and 21.1% females) in the control group and 104 patients in the treatment group (76.9% males and 23.1% females).

The mean age of all patients (between 13 to 64 years) was 33.29 ± 11.39 years (Mean ± SD). It was 33.86 ± 11.45 years in the control group and 32.57 ± 11.32 years in the treatment group.

The major causes of burn were gas explosion (38%), flame (39.7%), self-immolation (17.3%), electrical burn (1.7%), and some others. All of them had second- and/or third-degree burn and more than 90% of them had head and neck, trunk, and extremities injury simultaneously.

After excluding 42 patients with inhalation injury, electrical and chemical burns, and the patients who died in the first 72 h, 195 patients remained in the study, including 110 patients in the control group (81.8% males and 18.2% females) and 85 in the treatment group (77.6% males and 22.4% females).

The mean percentage of TBSA burn was 64.50 ± 14.34 and 68.58 ± 14.55 for the levamisole and control groups, respectively, with the range of 50-100% and 50-95% TBSA.

Mortality among patients was 77 in the control group and 60 of the treatment group. There was no significant difference in mortality in the two groups (P = 0.929) Table 1.{Table 1}

In both groups, mortality was significantly more common in female patients (P = 0.009 and 0.031, respectively), but mortality was not significantly different in males and females of levamisole and control groups (P = 0.83 and 0.61, respectively).

Levamisole had no effect in reducing mortality in subgroups of different ages (P value between 0.479 and 1) Table 2.{Table 2}

Also, the mortality rate was not significantly different between the two groups at different percentages of burns (P value between 0.66 and 1) Table 3.{Table 3}

There were significant differences between the two groups in plasma transfusion (P = 0.03) and escharotomy surgery (P = 0.04). The transfusion and escharotomy indications and need were lower in levamisole group.

The differences in the debridement number (P = 0.2) and graft surgery (P = 0.11) were not significant.

Discussion

Even with advances in burn care over recent decades, the treatment of patients with extensive burns remains a major challenge. 1,45 Recent data from the United States indicate 69% mortality among the patients with burns over 70% of TBSA. 45

The immune system is altered after thermal injury. The severity of immune suppression correlates with the severity of injury. Depressed immune system is one of the major causes of the susceptibility of these patients to infection and sepsis. The humoral immunity is altered, as seen by the decreased levels of immunoglobulins, activation of complement, release of anaphylatoxins, and formation of membrane-attacking complexes. Also, the specific immune response is altered after burn, which includes a depressed ability to produce active rosette-forming cells, depressed stimulation of lymphocyte proliferation, as well as the mixed lymphocyte response. These effects are modulated by the release of kinins, prostaglandins, anaphylatoxins, superoxides, and leukotrienes, all of which can influence the inflammatory response following thermal injury. The immune response is also influenced by some drugs used for other reasons such as steroids, chemotherapeutic agents, and topical agents used for burn wound care. 46,47,48

Any modulation that can improve the host defense mechanism has a beneficial effect on the rate of sepsis and infection and can decrease the mortality rate of burned patients. The study results of Stinnett et al. showed that immunomodulators could be of benefit in burns; however, not all agents are effective. 40

Levamisole, a synthetic phenylimidazolthiazole, is a potent antihelmintic agent that was first introduced in 1966. 1,49

After a few years, it was found that this drug had immunotropic properties and seemingly restored inefficient host defense mechanisms. 50

In many clinical trials and experimental studies, it has been used as an immunomodulation agent for the treatment of cancers, viral and bacterial infections, and aphthous lesions. Moreover, there are many studies about the mechanism of its action over immune system. 1,2,3,6,9,18,51,52 It is also useful in the treatment of leprosy, based on an Indian clinical trial. 2,49

Levamisole has been found effective in the improvement of immune system in some studies and had no effects in some other studies.

Niedworok et al. found that the survival time of the transplants was prolonged significantly by levamisole in healthy rabbits and was diminished in rabbits with burn disease. 42

In a study on burned animals, it was found that continuous infusion of levamisole treatment significantly increased the inflammatory response. 41 The study by Matchin showed that levamisole, antioxidants, and hyperbaric oxygenation facilitated most rapid recovery of the immunological status in burned patients. 43

In Stinnett et al.′s study in animal model, oral administration of levamisole did not reduce mortality in burned guinea pig, which was infected with Pseudomonas microorganism. 40

The price of levamisole is low and has a few side effects if it is used for a short period of time. The plasma elimination half-life of levamisole is between 3 and 4 h. Levamisole is metabolized by the liver and the metabolites are excreted mainly by the kidneys (70% over 3 days). The elimination half-life of metabolite excretion is approximately 16 h, and 5% is excreted in the feces. 53

The complications of levamisole include nausea, vomiting, fever, dizziness, headache, skin eruptions, mild anemia, and elevation of liver enzymes. Rare cases of side effects include agranulocytosis, thrombocytopenia, convulsion, and leukoencephalopathy. We did not evaluate the complications of the medication in our patients because the same complications are common in severely burned patients. 31,32,54,55,56,57

This study indicated no significant relationship between mortality and improvement outcome with levamisole consumption in the patients with third-degree burn with more than 50% of TBSA. This meant that the levamisole group had an equivalent chance for improvement in comparison with the control group.

Our study has some limitations. First of all, we did not measure any immunological response such as immunoglobulin or immune cellular functions. We only evaluated the mortality as an index of better immunity of the patients and it is not enough.

Extensively burned patients were selected for this study. These patients had a high mortality rate and the immune modulation may be insufficient for reducing mortality in these patients. Also, the gastrointestinal absorption of the medication was not predictable in the victims of extensive burns and the blood level of levamisole was not measured.

Although this study showed no beneficial effect of levamisole in extensively burned patients, repetition of the study for less-extensively burned patients and evaluation of blood level of levamizole during the study can clarify the immunomodulation and infection-prevention effects of this medication in thermal injury.

Conclusion

Based on these findings, it can be suggested that levamisole consumption in second- and third-degree burn patients with the TBSA of more than 50% had no effect on mortality rate. It appears that more randomized trials with less-extensively burned patients are required to evaluate the exact blood level of levamisole in order to fully establish the efficacy of levamisole on the improvement and mortality rate of these patients.

Brusselaers N Hoste EA Monstrey S Colpaert KE De Waele JJ Vandewoude KH Outcome and changes over time in survival following severe burns from 1985 to 2004Intensive Care Med 2005 31 1648 53 Olaitan PB Olaitan JO Burns and scalds - epidemiology and prevention in a developing countryNiger J Med 2005 14 9 16 O′Keefe GE Hunt JL Purdue GF An evaluation of risk factors for mortality after burn trauma and the identification of gender-dependent differences in outcomesJ Am Coll Surg 2001 192 153 60 Angus DC Wax RS Epidemiology of sepsis: An updateCrit Care Med 2001 29(7 Suppl) S109 16 Abraham E Matthay MA Dinarello CA Vincent JL Cohen J Opal SM Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluationCrit Care Med 2000 28 232 5 Ekenna O Sherertz RJ Bingham H Natural history of bloodstream infections in a burn patient population: The importance of candidemiaAm J Infect Control 1993 21 189 95 Bruitt BA Jr The diagnosis and treatment of infection in burn patientsBurns 1984 11 79 91 Howes RM Allen RC Su CT Hoopes JE Altered polymorphonuclear leukocyte bioenergetics in patients with thermal injurySurg Forum 1976 27 558 60 Howard RJ Simmons RL Acquired immunologic deficiencies after trauma and surgical proceduresSurg Gynecol Obstet 1974 139 771 82 Edwards-Jones V Greenwood JE; Manchester Burns Research Group What′s new in burn microbiology?Burns 2003 29 15 24 O′Sullivan ST O′Connor TP Immunosuppression following thermal injury: The pathogenesis of immunodysfunctionBr J Plast Surg 1997 50 615 23 Lederer JA Rodrick ML Mannick JA The effects of injury on the adaptive immune responseShock 1999 11 153 9 Gennari R Alexander JW Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defenseCrit Care Med Crit Care Med 1995 23 1945 53 Schlüter B König W Köller M Erbs G Müller FE Differential regulation of T- and B-lymphocyte activation in severely burned patientsJ Trauma 1991 31 239 46 Schlüter B König W Köller M Erbs G Müller FE Studies on B-lymphocyte dysfunctions in severely burned patientsJ Trauma 1990 30 1380 9 McIrvine AJ O′Mahony JB Saporoschetz I Mannick JA Depressed immune response in burn patients: Use of monoclonal antibodies and functional assay to define the role of suppressor cellsAnn Surg 1982 196 297 304 Sakai H Daniels JC Beathard GA Lewis SR Lynch JB Ritzmann SE Mixed lymphocyte culture reaction in patients with acute thermal BurnsJ Trauma 1974 14 53 7 Calvano SE deRiesthal HF Marano MA Antonacci AC The decrease in peripheral blood CD4 and T-cell following thermal injury in human can be accounted for by a concomitant decrease in suppressor-inducer CD4 and T cells as assessed using anti CD4Clin Immunol Immunopathol 1988 47 164 73 Ninnemann JL Trauma, Sepsis and the immune responseJ Burn Care Rehabil 1987 8 462 8 Guo Z Kavanagh E Zang Y Dolan SM Krignovich SJ Mannick JA Burn injury promotes antigen-driven Th2-type responses in vivoJ Immunol 2003 171 3983 90 Kelly JL O′Suilleabhain CB Soberg CC Mannick JA Lederer JA Severe injury triggers antigen-specific T-helper cell dysfunctionShock 1999 12 39 45 O′Sullivan ST Lederer JA Horgan AF Chin DH Mannick JA Rodrick ML Major injury leads to predominance of T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infectionAnn Surg 1995 222 482 90 Lyons A Kelly JL Rodrick ML Mannick JA Lederer JA Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection.AnnAnn Surg 1997 226 450 8 Gough DB Moss NM Jordan A Grbic JT Rodrick ML Mannick JA Recombinant Interleukin-2 improves immune response and host resistance to septic challenge in thermally injured miceSurgery 1988 104 292 300 Alexander JW Alteration of opsonic activity after burn injury, proceeding of the 40 th Anniversary symposium U.SArmy institute or surgical research Alteration of opsonic activity after burn injury, proceeding of the 40 th Anniversary symposium US Army institute or surgical research Fortsam Houston Texas: 1989, 126 Renoux G Renoux M Modulation of immune reactivity by phenylimidothiazole salts in mice immunized by sheep red blood cellsJ Immunol 1974 113 779 90 Brunner CJ Muscoplat CC Immunomodulatory effects of LevamisoleJ Am Vet Med Assoc 1980 176 1159 62 Symoens J Rosenthal M Levamisole in the modulation of the immune response: The current experimental and clinical stateJ Reticuloendothel Soc 1977 21 175 221 Szeto C Gillespie KM Mathieson PW Levamisole induces interleukin-18 and shifts type 1/type2 cytokine balanceImmunology 2000 100 217 24 Boziæ F Biliæ V Valpotiæ I Modulating by Levamisole of CD45RA and CD45RC isoforms expression in gut of weaned pigs vaccinated against colibacillosisJ Vet Pharmacol Ther 2002 25 69 72 Hibi D Imazawa T Kijima A Suzuki Y Ishii Y Jin M Investigation of carcinogenicity for levamisole administered in the diet to F344 ratsFood Chem Toxicol 2010 48 3321 6 Boyer O Moulder JK Grandin L Somers MJ Short- and long-term efficacy of levamisole as adjunctive therapy in childhood nephrotic syndromePediatr Nephrol 2008 23 575 80 Ejlertsen B Mouridsen HT Jensen MB Andersen J Andersson M Kamby C Cyclophosphamide, methotrexate, and fluorouracil; Oral cyclophosphamide; Levamisole; or no adjusant therapy for patients with high-risk, premenopausal breast cancerCancer 2010 116 2081 9 Sayad B Alavian SM Najafi F Soltani B Shirvani M Janbakhsh A Effects of oral levamisole as an adjuvant to hepatitis b vaccine in HIV/ AIDS patients: A randomized controlled trialHepat Mon 2012 12 e6234 Boziæ F Lackoviæ G Kovsca-Janjatoviæ A Smolec O Valpotiæ I Levamisole synergizes experimental F4ac+ Escherchiacoli oral vaccine in stimulating ileal peyer′s patch T cell in weaned pigs.JVet Levamisole synergizes experimental F4ac+ Escherchiacoli oral vaccine in stimulating ileal peyer's patch T cell in weaned pigs J Vet pharmacol J Vet Pharmacol Ther 2006;29:199-204 Janjatoviæ AK Lackoviæ G Boziæ F Popoviæ M Valpotiæ I Levamisole synergizes proliferation of intestinal IgA+ cells in weaned pigs immunized with vaccine candidate F4ac+ nonenterotoxigenic Esherchia coli strainJ Vet Pharmacol Ther 2008 31 328 33 Fata F Mirza A Craig G Nair S Law A Gallagher J Efficacy and toxicity of adjuvant therapy in elderly patients with colon carcinoma: A 10 years experience of the Geisinger Medical centerCancer 2002 94 1931 8 Grinev MV Cytoreductive surgery as an alternative to palliative operation in oncologyVestn Khir Im I I Grek 2002 161 100 3 Karaoglan M Demirci F Coskun Y Karaoglan L Bayraktaroglu Z Okan V Immunomodulation therapy in children with chronic hepatitis BJ Natl Med Assoc 2006 98 143 7 Stinnett JD Loose LD Miskell P Tenney CL Gonce SJ Alexander JW Synthetic immunomodulators for prevention of fatal infection in a burned guiea pig modelAnn Surg 1983 198 53 7 McManus AT Examination of neutrophil function in a rat model of decreased host resistance following burn traumaRev Infect Dis 1983 5 (Suppl 5) S898 907 Niedworok J Offierska M Lambrecht W Effect of Levamisole on the survival time of skin Transplants in burnZ Exp Chir 1980 13 151 4 Matchin EN Atiasov NI Zuev PD Vinogradova GV Methods of correction of humeral and cellular immunity in patients with burns and erosive-ulcerative Levamisole lesions of the gastrointestinal tractVestn Khir Im I I Grek 1990 144 44 9 Wang Y Tang HT Xia ZF Zhu SH Ma B Wei W Factors affecting survival in adult patients with massive burnsBurns 2010 36 57 64 American Burn Association National Burn Repository 2005 reportpdf] //. 3. National Burn Repository 2005 report Available from: http://WWWameriburnorg/NBR2005pdf] 08/03/2013 Alexander JW Serum and Leukocyte lysosomal enzymes: Derangements following severe thermal injuryArch Surg 1967 95 482 91 Schwacha MG Somers SD Thermal injury-induced immunosuppression in mice.The role of macrophage-derived reactive nitrogen intermediatesJ Leukoc Biol 1998 63 51 8 Heideman M Bengtsson A The immunologic response to thermal injuryWorld J Surg 1992 16 53 6 Chen LY Lin YL Chiang BL Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cellsBritish Society for Immunology, Clin Exp Immunol 2007 151 174 81 Swierenga J Gooszen HC Vanderschueren RG Cosemans J Louwagie A Stam J Immunopotentiation with levamisole in resectable bronchogenic carcinoma: A double-blind controlled trial, study group for bronchogenic carcinomaBr Med J 1975 3 461 4 Hedge M Karki SS Thomas E Kumar S Panjamurthy K Ranganatha SR Novel levamisole derivative induces extrinsic pathway of apoptosis in cancer cell and inhabits tumor progression in micePlos One 2012 7 1 13 Al-Ibrahim AA Al-kharraz SM Al-Sadoon DM Al-Madani AJ Al-Musallam SA Levamisole therapy as a second - line immunosuppressive agent in corticosteroid - sensitive nephritic Syndrome in childrenSaudi J Kidney Dis Transplant 2003 14 153 7 Argani H Akhtarishojaie E Levamizole enhances immune responsiveness to intra-dermal and intra-muscular hepatitis B vaccination in chronic hemodialysis patientsJ Immune Based Ther Vaccines 2006 4 3 Ching JA Smith DJ Jr Levamisole-induced necrosis of skin, soft tissue, and bone: Case report and review of literatureJ Burn Care Res 2012 33 e1 5 Won TH Park SY Kim BS Seo PS Park SD Levamisole monotherapy for oral lichen planusAnn Dermatol 2009 21 250 4 Xu N Zhou W Li S Zhou G Zhang N Liang J Clinical and MRI characteristics of levamisole-induced leukoencephalopathy in 16 patientsJ Neuroimaging 2009 19 326 31 Lee KC Ladizinski B Federman DG Complications associated with use of levamisole-contaminated cocaine: An emerging public health challengeMayo Clin Proc 2012 87 581 6